ECM
TVRD

Everence Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Everence Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-309
Closed -$120 – 795
2022
Q4 		$120 Buy
+309
New +$117K 0.01% 739
2022
Q1 		– Sell
-481
Closed -$211K – 793
2021
Q4 		$211K Buy
+481
New +$242K 0.02% 716

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Everence Capital Management's TVRD Position: Q1 2023 in Review

Everence Capital Management sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 309 shares — an estimated $120 sold.

Everence Capital Management first reported a position in TVRD in Q4 2021 and held it in 2 quarters. The position peaked at $211K in Q4 2021. 163 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Everence Capital Management reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Everence Capital Management sold 309 Tvardi Therapeutics shares in Q1 2023, an estimated $120.
  • Everence Capital Management first reported a position in Tvardi Therapeutics in Q4 2021 and held it in 2 quarters.
  • Everence Capital Management's Tvardi Therapeutics position peaked at $211K in Q4 2021.
  • 163 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Everence Capital Management's 13F filing for Q1 2023, filed 4 Apr 2023.